Activators of the olfactory receptor OR4K14 exert their influence through various biochemical mechanisms that modulate the intracellular concentrations of cyclic nucleotides such as cAMP and cGMP. The activation process often involves the direct stimulation of adenylyl cyclase, an enzyme that catalyzes the conversion of ATP to cAMP, a secondary messenger intimately involved in the signaling processes of G protein-coupled receptors like OR4K14. The elevation of intracellular cAMP levels by certain activators reinforces the signaling cascade that ultimately potentiates the functional activity of OR4K14. Additionally, the inhibition of phosphodiesterases (PDEs), enzymes responsible for the breakdown of cAMP and cGMP, is another approach through which activators indirectly sustain enhanced receptor signaling. By preventing the degradation of these cyclic nucleotides, activators ensure a prolonged and amplified response of OR4K14 to its ligands.
Certain activators utilize a more targeted approach by specifically inhibiting types of PDEs, thereby increasing cAMP concentrations in a more controlled manner, leading to selective activation of OR4K14. Other activators may influence G protein-coupled receptor signaling through modulation of metal ion concentration, such as zinc, which is known to affect the function of a wide array of receptors. By manipulating the signaling environment in which OR4K14 operates, these activators indirectly foster an increase in the receptor's activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor, which prevents cAMP degradation, potentiating OR4K14. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist that elevates intracellular cAMP, thereby could activate OR4K14. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Inhibits PDE3, increasing cAMP concentration, which might lead to the activation of OR4K14. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
PDE4 inhibitor, enhances cAMP levels, indirectly promoting OR4K14 signaling. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Can modulate G protein-coupled receptor signaling, potentially enhancing OR4K14 function. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Non-selective PDE inhibitor, increases cAMP levels, potentially enhancing OR4K14 activity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
PDE3 inhibitor, increases cAMP levels, which might lead to the activation of OR4K14. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Non-selective PDE inhibitor, increases cAMP, which could indirectly activate OR4K14. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
PDE1 inhibitor, increases cAMP and cGMP levels, potentially activating OR4K14. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
PDE5 inhibitor, leading to increased cAMP and cGMP, which may enhance OR4K14 activity. | ||||||